220 results about "Immune correlates" patented technology

The present invention relates generally to methods for stimulating cells, and more particularly, to a novel method to concentrate and stimulate cells that maximizes stimulation and / or proliferation of such cells. In the various embodiments, cells are stimulated and concentrated with a surface yielding enhanced proliferation, cell signal transduction, and / or cell surface moiety aggregation. In certain aspects methods for stimulating a population of cells such as T-cells, by simultaneous concentration and cell surface moiety ligation are provided by contacting the population of cells with a surface, that has attached thereto one or more agents that ligate a cell surface moiety and applying a force that predominantly drives cell concentration and cell surface moiety ligation, thereby inducing cell stimulation, cell surface moiety aggregation, and / or receptor signaling enhancement. Also provided are methods for producing phenotypically tailored cells, including T-cells for the use in diagnostics, drug discovery, and the treatment of a variety of indications, including cancer, viral infection, and immune related disorders. Compositions of cells having specific phenotypic properties produced by these processes are further provided.

The present invention relates generally to methods for stimulating cells, and more particularly, to a novel method to concentrate and / or stimulate cells that maximizes stimulation and / or proliferation of such cells. In the various embodiments, cells are stimulated and concentrated with a surface yielding enhanced proliferation, cell signal transduction, and / or cell surface moiety aggregation. In certain aspects methods for stimulating a population of cells such as T-cells, by simultaneous concentration and cell surface moiety ligation are provided by contacting the population of cells with a surface, that has attached thereto one or more agents that ligate a cell surface moiety and applying a force that predominantly drives cell concentration and cell surface moiety ligation, thereby inducing cell stimulation, cell surface moiety aggregation, and / or receptor signaling enhancement. Also provided are methods for producing phenotypically tailored cells, including T-cells for the use in diagnostics, drug discovery, and the treatment of a variety of indications, including cancer, viral infection, and immune related disorders. Compositions of cells having specific phenotypic properties produced by these processes are further provided.

The invention relates to compounds of structural formula (I) or (III): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein ring A, X1, X2, X3, X5, R1, R4, Y, Z, L, m and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

The invention relates to compounds of structural formula (Ia): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X1, X2, X3, X4, X6, X10, R1, Y, Z, L, and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

The present invention relates to novel process for the preparation of glycoproteins by mammalian cell culture wherein the sialic acid content of the glycoprotein produced is controlled over a broad range of values by manipulating the cell culture environment. The invention provides for processes in which the sialic acid content of the glycoprotein is modified by changes in cell culture parameters which affect cell specific productivity. Preferred embodiments of the invention include cell culture processes in the osmolality of the cell culture is controlled as well as the concentration of a transcription enhancer during the production phase of the cell culture. The invention further provides for novel preparations of soluble type 1 tumor necrosis factor immunoglobulin G1 and their uses in the treatment of inflammatory or immune related disorders.

The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein R′1, X, X′, L and Y are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

The invention relates to compounds of structural formulas (I) and (XVI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X1, X2, Z, L, L2, R1, R2, R3, R21, n, q, and t are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Compounds that modulate the oxidoreductase enzyme indoleamine 2,3- dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and / or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.

Fusion proteins having sequences that target specific moieties such as carbohydrates, lipids, and / or proteins that are associated with certain cell types and / or pathogens; and a sequence that induces effector function are provided. The disclosure also provides nucleic acids encoding the fusion proteins, as well as pharmaceutical compositions, methods of use, and methods of treating conditions or diseases such as infectious diseases, cancers, immune related disorders and other ailments, that include the fusions proteins described herein.

The invention relates to fully human antibodies, and fragments thereof, that bind to human interferon gamma (hIFNγ), thereby modulating the interaction between IFNγ and its receptor, IFNγ-R, and / or modulating the biological activities of IFNγ. The invention also relates to the use of such anti-IFNγ antibodies in the prevention or treatment of immune-related disorders and in the amelioration of a symptom associated with an immune-related disorder.

Compounds, compositions and methods that are useful in the treatment of inflammatory and immune-related diseases and conditions are provided herein. In particular, the invention provides compounds which modulate the function and / or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.

The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and / or inflammatory diseases.

The invention provides a small molecule compound. The small molecule compound is characterized in that the small molecule compound is a compound shown in a structural formula in the specification, ora stereoisomer, a geometric isomer, a tautomer, a racemate, a hydrate, a solvate, a metabolite, and a pharmaceutically acceptable salt or pro-drug thereof, wherein X1 and X2 are selected from carbon or nitrogen; Z is carbon or nitrogen; n1 is 0 and 1; n2 and n3 are the same or different, and are 0 or any natural numbers; a cyclic group represented by G is a saturated heterocyclic ring; any one orseveral hydrogen atoms on the saturated heterocyclic ring are substituted by R; and R is selected from hydrogen, halogen, alkyl, substituted alkyl, amino, amine group, substituted amine group, carboxyl, amido, substituted amido, ester group, substituted carbonyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, substituted sulfonyl, and substituted sulfoxide group. The small molecule compound of the invention can be used to treat, prevent and alleviate autoimmune diseases and / or immune-related inflammatory skin diseases.

We identified regions of the HIV-1 proteome with high conservation, and low variant incidence. Such highly conserved sequences have direct relevance to the development of new-generation vaccines and diagnostic applications. The immune relevance of these sequences was assessed by their correlation to previously reported human T-cell epitopes and to recently identified human HIV-1 T-cell epitopes (identified using HLA transgenic mice). We identified (a) sequences specific to HIV-1 with no shared identity to other viruses and organisms, and (b) sequences that are specific to primate lentivirus group, with multiclade HIV-1 conservation.

The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-I in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided.

The invention discloses a tumor immune subtype classification method and a tumor immune subtype classification system. The method comprises the following steps: acquiring a sample data set comprisingRNA-seq sequencing data and gene expression profile data of a plurality of tumor tissues; calculating microorganism abundance data, immune cell proportion data and gene expression data related to immunity in the tumor tissue corresponding to each sample in the sample data set; constructing a training sample data set by taking microorganism abundance data, immune cell proportion data and gene expression data related to immunity as classification features, expanding minority classes by adopting an SMOTE algorithm, training a random forest model, and improving the random forest model in a weighting form: increasing the weight of the minority classes. And thus, the decision tree classifier focuses on the minority class, and the classification accuracy of the minority class is improved. According to the invention, the accuracy of tumor immune subtype classification prediction can be improved, and a new target is provided for tumor immunotherapy.

The present invention relates to a method for the treatment of immune-related disorders in a mammalian subject in need of such treatment. This method comprises the step of manipulating the NK T cell population in said subject by suitable means, said manipulation of the NK T cell population resulting in modulation of the Th1 / Th2 balance toward anti-inflammatory cytokine producing cells. Manipulation of the NK T cell population may be performed either by depletion of said cells by a suitable means or alternatively by ex vivo education of the NK T cells, such that the educated NK T cells have the capability to modulate the Th1 / Th2 balance toward anti-inflammatory cytokine producing cells. The invention further relates to pharmaceutical compositions for the treatment of immune-related disorders in a mammalian subject. These compositions comprising as an effective ingredient an ex vivo educated NK T cell. The invention further provides for an ex vivo educated NK T cell and uses thereof in the treatment of immune-related disorders.

The invention relates to the technical field of an application of bacteroides fragilis (BF) 839, in particular to an application of the bacteroides fragilis 839 to preparation of a medicine or food for treating or adjunctively treating immune-related diseases. The key effect of the bacteroides fragilis 839 in human intestinal tracts in treatment or adjuvant treatment of the immune-related diseasesis discovered for the first time, and the bacteroides fragilis 839 can be made into forms of pharmaceutical compositions, foods, health-care products or food additives by utilizing the key effect ofthe bacteroides fragilis 839 in the immune-related diseases. A pharmaceutical composition, a food, a health-care product or a food additive contains the bacteroides fragilis 839, can be used for treating the immune-related diseases, and has very important application value.

Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and / or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are tetrahydroquinoline derivatives.

Methods and tools for assessing the prognosis for patients following treatment of primary tumors are provided. The methods involve identifying immune-related genetic markers whose differential expression patterns at tumor lesions are indicative of either tumor recurrence or recurrence-free survival. The methods and tools of the invention assist physicians by providing objective decision-making tools for planning patient treatment protocols.

The present invention belongs to the field of food and medicine technology, and especially water soluble Agaricus blazei murrill polysaccharide extracted from Agaricus blazei murrill sporophore or mycelium and its preparation process. The extract has molecular weight over 10,000, and is prepared through one of two extraction process. One of the extraction process includes ethanol extraction to eliminate water soluble small molecular weight impurity, water extraction to obtain water soluble polysaccharide and direct concentration of the water extracted matter; and the other includes hot water extraction, ultrafiltration with ultrafiltering film of intercepting molecular weight 4,000, and concentration of the matter on the ultrafilter membrane. Experiment shows that the extract has obvious tumor cell growth inhibiting effect, obtain immune regulating function and no toxic side effect, and may be used in preparing medicine and functional health food for preventing and treating relevant diseases.

The invention provides a construction method of an IL7R gene humanized modified animal model, a humanized IL7R protein, a humanized IL7R gene, a targeting vector of the IL7R gene and an application ofthe targeting vector in the field of biological medicines. A part of nucleotide sequences for coding the human IL7R protein are introduced into a non-human animal genome in a homologous recombinationmanner, and the animal model can normally express the humanized IL7R protein in vivo, and can be used for human IL7R signal mechanism research, tumor and immune related disease drug screening, and important application value is realized on the research and development of new drugs of immune targets.

The present invention relates to novel process for the preparation of glycoproteins by mammalian cell culture wherein the sialic acid content of the glycoprotein produced is controlled over a broad range of values by manipulating the cell culture environment. The invention provides for processes in which the sialic acid content of the glycoprotein is modified by changes in cell culture parameters which affect cell specific productivity. Preferred embodiments of the invention include cell culture processes in the osmolality of the cell culture is controlled as well as the concentration of a transcription enhancer during the production phase of the cell culture. The invention further provides for novel preparations of soluble type 1 tumor necrosis factor immunoglobulin G1 and their uses in the treatment of inflammatory or immune related disorders.

The invention discloses application of an Amurensin H derivative EAPP shown in a formula (I) in preparation of products for treating and / or preventing aplastic anemia. The Amurensin H derivative EAPPdisclosed by the invention is simple in preparation method, has obvious anti-inflammatory activity, has a remarkable treatment effect on the aplastic anemia, can be applied to clinical treatment of the aplastic anemia in a form of a monomer or a medicinal composition, and has potential application value in treatment of the aplastic anemia and immune-related diseases.

The invention discloses an immunity-related biomarker and an application of the biomarker to prognosis diagnosis of head and neck squamous cell carcinoma. The biomarker comprises four immune-related genes PVR, TNFRSF12A, IL-21R and SOCS1, and the biomarker and Path_N jointly form a head and neck squamous cell carcinoma prediction prognosis model. A group of new high-sensitivity and specific immunity-related molecular markers are developed for HNSCC prediction prognosis diagnosis to improve the outcome of a patient, which meets the current urgent demands. A model detection method is simple andeasy to operate, helps to better identify HNSCC patients, and can be used as a guidance basis for HNSCC immunotherapy decisions.